ID   BMPR2_HUMAN             Reviewed;        1038 AA.
AC   Q13873; Q13161; Q16569; Q4ZG08; Q53SA5; Q585T8;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   12-OCT-2022, entry version 229.
DE   RecName: Full=Bone morphogenetic protein receptor type-2;
DE            Short=BMP type-2 receptor;
DE            Short=BMPR-2;
DE            EC=2.7.11.30;
DE   AltName: Full=Bone morphogenetic protein receptor type II;
DE            Short=BMP type II receptor;
DE            Short=BMPR-II;
DE   Flags: Precursor;
GN   Name=BMPR2; Synonyms=PPH1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RC   TISSUE=Kidney;
RX   PubMed=7791754; DOI=10.1128/mcb.15.7.3479;
RA   Liu F., Ventura F., Doody J., Massague J.;
RT   "Human type II receptor for bone morphogenic proteins (BMPs): extension of
RT   the two-kinase receptor model to the BMPs.";
RL   Mol. Cell. Biol. 15:3479-3486(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Substantia nigra;
RX   PubMed=7644468; DOI=10.1073/pnas.92.17.7632;
RA   Rosenzweig B.L., Imamura T., Okadome T., Cox G.N., Yamashita H.,
RA   ten Dijke P., Heldin C., Miyazono K.;
RT   "Cloning and characterization of a human type II receptor for bone
RT   morphogenetic proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7632-7636(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Skin fibroblast;
RX   PubMed=7673243; DOI=10.1074/jbc.270.38.22522;
RA   Nohno T., Ishikawa T., Saito T., Hosokawa K., Noji S., Wosing D.H.,
RA   Rosenbaum J.S.;
RT   "Identification of a human type II receptor for bone morphogenetic protein-
RT   4 that forms differential heteromeric complexes with bone morphogenetic
RT   protein type I receptors.";
RL   J. Biol. Chem. 270:22522-22526(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7890683; DOI=10.1074/jbc.270.10.5625;
RA   Kawabata M., Chytil A., Moses H.L.;
RT   "Cloning of a novel type II serine/threonine kinase receptor through
RT   interaction with the type I transforming growth factor-beta receptor.";
RL   J. Biol. Chem. 270:5625-5630(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-586, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-379, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [10]
RP   INTERACTION WITH GDF5.
RX   PubMed=21976273; DOI=10.1002/jbmr.532;
RA   Schwaerzer G.K., Hiepen C., Schrewe H., Nickel J., Ploeger F., Sebald W.,
RA   Mueller T., Knaus P.;
RT   "New insights into the molecular mechanism of multiple synostoses syndrome
RT   (SYNS): mutation within the GDF5 knuckle epitope causes noggin-
RT   resistance.";
RL   J. Bone Miner. Res. 27:429-442(2012).
RN   [11]
RP   INTERACTION WITH BMP4.
RX   PubMed=29212066; DOI=10.1159/000485759;
RA   Jin X., Nie E., Zhou X., Zeng A., Yu T., Zhi T., Jiang K., Wang Y.,
RA   Zhang J., You Y.;
RT   "Fstl1 Promotes Glioma Growth Through the BMP4/Smad1/5/8 Signaling
RT   Pathway.";
RL   Cell. Physiol. Biochem. 44:1616-1628(2017).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   INTERACTION WITH SCUBE3.
RX   PubMed=33308444; DOI=10.1016/j.ajhg.2020.11.015;
RG   Genomics England Research Consortium;
RA   Lin Y.C., Niceta M., Muto V., Vona B., Pagnamenta A.T., Maroofian R.,
RA   Beetz C., van Duyvenvoorde H., Dentici M.L., Lauffer P., Vallian S.,
RA   Ciolfi A., Pizzi S., Bauer P., Gruening N.M., Bellacchio E.,
RA   Del Fattore A., Petrini S., Shaheen R., Tiosano D., Halloun R.,
RA   Pode-Shakked B., Albayrak H.M., Isik E., Wit J.M., Dittrich M.,
RA   Freire B.L., Bertola D.R., Jorge A.A.L., Barel O., Sabir A.H.,
RA   Al Tenaiji A.M.J., Taji S.M., Al-Sannaa N., Al-Abdulwahed H., Digilio M.C.,
RA   Irving M., Anikster Y., Bhavani G.S.L., Girisha K.M., Haaf T., Taylor J.C.,
RA   Dallapiccola B., Alkuraya F.S., Yang R.B., Tartaglia M.;
RT   "SCUBE3 loss-of-function causes a recognizable recessive developmental
RT   disorder due to defective bone morphogenetic protein signaling.";
RL   Am. J. Hum. Genet. 108:115-133(2021).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 33-131, AND DISULFIDE BONDS.
RX   PubMed=17094948; DOI=10.1016/j.bbrc.2006.10.109;
RA   Mace P.D., Cutfield J.F., Cutfield S.M.;
RT   "High resolution structures of the bone morphogenetic protein type II
RT   receptor in two crystal forms: implications for ligand binding.";
RL   Biochem. Biophys. Res. Commun. 351:831-838(2006).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 189-517 IN COMPLEX WITH ADP.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the BMPR2 kinase domain.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [16]
RP   VARIANTS PPH1 GLN-491 AND TRP-491.
RX   PubMed=10903931; DOI=10.1086/303059;
RA   Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G.,
RA   Kalachikov S., Cayanis E., Fischer S.G., Barst R.J., Hodge S.E.,
RA   Knowles J.A.;
RT   "Familial primary pulmonary hypertension (gene PPH1) is caused by mutations
RT   in the bone morphogenetic protein receptor-II gene.";
RL   Am. J. Hum. Genet. 67:737-744(2000).
RN   [17]
RP   VARIANTS PPH1 TYR-60; TYR-117 AND ARG-483.
RX   PubMed=11015450; DOI=10.1136/jmg.37.10.741;
RA   Thomson J.R., Machado R.D., Pauciulo M.W., Morgan N.V., Humbert M.,
RA   Elliott G.C., Ward K., Yacoub M., Mikhail G., Rogers P., Newman J.H.,
RA   Wheeler L., Higenbottam T., Gibbs J.S.R., Egan J., Crozier A., Peacock A.,
RA   Allcock R., Corris P., Loyd J.E., Trembath R.C., Nichols W.C.;
RT   "Sporadic primary pulmonary hypertension is associated with germline
RT   mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta
RT   family.";
RL   J. Med. Genet. 37:741-745(2000).
RN   [18]
RP   VARIANTS PPH1 TRP-118; TYR-347 AND GLY-485.
RX   PubMed=10973254; DOI=10.1038/79226;
RA   Lane K.B., Machado R.D., Pauciulo M.W., Thomson J.R., Phillips J.A. III,
RA   Loyd J.E., Nichols W.C., Trembath R.C., Aldred M., Brannon C.A.,
RA   Conneally P.M., Foroud T., Fretwell N., Gaddipati R., Koller D., Loyd E.J.,
RA   Morgan N.V., Newman J.H., Prince M.A., Vilarino Gueell C., Wheeler L.;
RT   "Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor,
RT   cause familial primary pulmonary hypertension.";
RL   Nat. Genet. 26:81-84(2000).
RN   [19]
RP   VARIANTS PPH1 ARG-123; SER-123; ARG-420 AND THR-512, VARIANT ASP-224, AND
RP   CHARACTERIZATION OF VARIANT PPH1 GLY-485.
RX   PubMed=11115378; DOI=10.1086/316947;
RA   Machado R.D., Pauciulo M.W., Thomson J.R., Lane K.B., Morgan N.V.,
RA   Wheeler L., Phillips J.A. III, Newman J.H., Williams D., Galie N.,
RA   Manes A., McNeil K., Yacoub M., Mikhail G., Rogers P., Corris P.,
RA   Humbert M., Donnai D., Martensson G., Tranebjaerg L., Loyd J.E.,
RA   Trembath R.C., Nichols W.C.;
RT   "BMPR2 haploinsufficiency as the inherited molecular mechanism for primary
RT   pulmonary hypertension.";
RL   Am. J. Hum. Genet. 68:92-102(2001).
RN   [20]
RP   VARIANTS PPH1 HIS-82; ASP-182 AND ARG-483.
RX   PubMed=12358323; DOI=10.1183/09031936.02.01762002;
RA   Humbert M., Deng Z., Simonneau G., Barst R.J., Sitbon O., Wolf M.,
RA   Cuervo N., Moore K.J., Hodge S.E., Knowles J.A., Morse J.H.;
RT   "BMPR2 germline mutations in pulmonary hypertension associated with
RT   fenfluramine derivatives.";
RL   Eur. Respir. J. 20:518-523(2002).
RN   [21]
RP   INVOLVEMENT IN PVOD1.
RX   PubMed=12446270; DOI=10.1164/rccm.200208-861oc;
RA   Runo J.R., Vnencak-Jones C.L., Prince M., Loyd J.E., Wheeler L.,
RA   Robbins I.M., Lane K.B., Newman J.H., Johnson J., Nichols W.C.,
RA   Phillips J.A. III;
RT   "Pulmonary veno-occlusive disease caused by an inherited mutation in bone
RT   morphogenetic protein receptor II.";
RL   Am. J. Respir. Crit. Care Med. 167:889-894(2003).
RN   [22]
RP   VARIANT PPH1 PRO-899, AND CHARACTERIZATION OF VARIANT PPH1 PRO-899.
RX   PubMed=15965979; DOI=10.1002/humu.20200;
RA   Sankelo M., Flanagan J.A., Machado R., Harrison R., Rudarakanchana N.,
RA   Morrell N., Dixon M., Halme M., Puolijoki H., Kere J., Elomaa O.,
RA   Kupari M., Raeisaenen-Sokolowski A., Trembath R.C., Laitinen T.;
RT   "BMPR2 mutations have short lifetime expectancy in primary pulmonary
RT   hypertension.";
RL   Hum. Mutat. 26:119-124(2005).
RN   [23]
RP   INVOLVEMENT IN PVOD1.
RX   PubMed=16429395; DOI=10.1002/humu.20285;
RA   Machado R.D., Aldred M.A., James V., Harrison R.E., Patel B.,
RA   Schwalbe E.C., Gruenig E., Janssen B., Koehler R., Seeger W.,
RA   Eickelberg O., Olschewski H., Elliott C.G., Glissmeyer E., Carlquist J.,
RA   Kim M., Torbicki A., Fijalkowska A., Szewczyk G., Parma J.,
RA   Abramowicz M.J., Galie N., Morisaki H., Kyotani S., Nakanishi N.,
RA   Morisaki T., Humbert M., Simonneau G., Sitbon O., Soubrier F., Coulet F.,
RA   Morrell N.W., Trembath R.C.;
RT   "Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial
RT   hypertension.";
RL   Hum. Mutat. 27:121-132(2006).
RN   [24]
RP   VARIANT [LARGE SCALE ANALYSIS] ASN-775.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [25]
RP   VARIANTS PPH1 LEU-77; PHE-84; TYR-87; LEU-92; PRO-162; ASN-264 AND MET-341,
RP   AND VARIANT ASN-775.
RX   PubMed=24936649; DOI=10.1371/journal.pone.0100261;
RA   Pousada G., Baloira A., Vilarino C., Cifrian J.M., Valverde D.;
RT   "Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic
RT   parameters in patients with pulmonary arterial hypertension.";
RL   PLoS ONE 9:E100261-E100261(2014).
RN   [26]
RP   VARIANTS PPH1 CYS-67 AND ASN-863, CHARACTERIZATION OF VARIANTS PPH1 CYS-67
RP   AND ASN-863, AND SUBCELLULAR LOCATION.
RX   PubMed=25187962; DOI=10.1371/journal.pone.0106703;
RA   Wang H., Ji R., Meng J., Cui Q., Zou W., Li L., Wang G., Sun L., Li Z.,
RA   Huo L., Fan Y., Penny D.J.;
RT   "Functional changes in pulmonary arterial endothelial cells associated with
RT   BMPR2 mutations.";
RL   PLoS ONE 9:E106703-E106703(2014).
RN   [27]
RP   VARIANTS PPH1 ARG-64; PHE-84; HIS-109; ALA-138; 218-TYR--LEU-1038 DEL;
RP   GLY-248; 298-TRP--LEU-1038 DEL AND ARG-467, CHARACTERIZATION OF VARIANTS
RP   PPH1 ARG-64; LEU-77; TYR-87; LEU-92; HIS-109; ALA-138; PRO-162;
RP   218-TYR--LEU-1038 DEL; GLY-248; ASN-264; 298-TRP--LEU-1038 DEL; MET-341 AND
RP   ARG-467, AND CHARACTERIZATION OF VARIANT ASN-775.
RX   PubMed=28507310; DOI=10.1038/s41598-017-02074-8;
RA   Pousada G., Lupo V., Castro-Sanchez S., Alvarez-Satta M.,
RA   Sanchez-Monteagudo A., Baloira A., Espinos C., Valverde D.;
RT   "Molecular and functional characterization of the BMPR2 gene in Pulmonary
RT   Arterial Hypertension.";
RL   Sci. Rep. 7:1923-1923(2017).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting of two
CC       type II and two type I transmembrane serine/threonine kinases. Type II
CC       receptors phosphorylate and activate type I receptors which
CC       autophosphorylate, then bind and activate SMAD transcriptional
CC       regulators. Binds to BMP7, BMP2 and, less efficiently, BMP4. Binding is
CC       weak but enhanced by the presence of type I receptors for BMPs.
CC       Mediates induction of adipogenesis by GDF6.
CC       {ECO:0000250|UniProtKB:O35607}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[receptor-protein] = ADP + H(+) + O-phospho-
CC         L-threonyl-[receptor-protein]; Xref=Rhea:RHEA:44880, Rhea:RHEA-
CC         COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977,
CC         ChEBI:CHEBI:456216; EC=2.7.11.30;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[receptor-protein] = ADP + H(+) + O-phospho-L-
CC         seryl-[receptor-protein]; Xref=Rhea:RHEA:18673, Rhea:RHEA-COMP:11022,
CC         Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, ChEBI:CHEBI:456216;
CC         EC=2.7.11.30;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Interacts with GDF5 (PubMed:21976273). Interacts with BMP4
CC       (PubMed:29212066). Interacts with SCUBE3 (PubMed:33308444).
CC       {ECO:0000269|PubMed:21976273, ECO:0000269|PubMed:29212066,
CC       ECO:0000269|PubMed:33308444}.
CC   -!- INTERACTION:
CC       Q13873; P43026: GDF5; NbExp=4; IntAct=EBI-527196, EBI-8571476;
CC       Q13873; Q13976: PRKG1; NbExp=2; IntAct=EBI-527196, EBI-3952014;
CC       Q13873; P08607: C4bpa; Xeno; NbExp=3; IntAct=EBI-527196, EBI-527325;
CC       Q13873; P68404: Prkcb; Xeno; NbExp=4; IntAct=EBI-527196, EBI-397048;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:25187962};
CC       Single-pass type I membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13873-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13873-2; Sequence=VSP_054441, VSP_054442;
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart and liver.
CC   -!- DISEASE: Pulmonary hypertension, primary, 1 (PPH1) [MIM:178600]: A rare
CC       disorder characterized by plexiform lesions of proliferating
CC       endothelial cells in pulmonary arterioles. The lesions lead to elevated
CC       pulmonary arterial pression, right ventricular failure, and death. The
CC       disease can occur from infancy throughout life and it has a mean age at
CC       onset of 36 years. Penetrance is reduced. Although familial pulmonary
CC       hypertension is rare, cases secondary to known etiologies are more
CC       common and include those associated with the appetite-suppressant
CC       drugs. {ECO:0000269|PubMed:10903931, ECO:0000269|PubMed:10973254,
CC       ECO:0000269|PubMed:11015450, ECO:0000269|PubMed:11115378,
CC       ECO:0000269|PubMed:12358323, ECO:0000269|PubMed:15965979,
CC       ECO:0000269|PubMed:24936649, ECO:0000269|PubMed:25187962,
CC       ECO:0000269|PubMed:28507310}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Pulmonary venoocclusive disease 1, autosomal dominant (PVOD1)
CC       [MIM:265450]: A disease characterized by widespread fibrous obstruction
CC       and intimal thickening of septal veins and preseptal venules, a low
CC       diffusing capacity for carbon monoxide, occult alveolar hemorrhage, and
CC       nodular ground-glass opacities, septal lines and lymph node enlargement
CC       showed by high-resolution computed tomography of the chest. It is
CC       frequently associated with pulmonary capillary dilatation and
CC       proliferation, and is a rare and devastating cause of pulmonary
CC       hypertension. {ECO:0000269|PubMed:12446270,
CC       ECO:0000269|PubMed:16429395}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U25110; AAA86519.1; -; mRNA.
DR   EMBL; Z48923; CAA88759.1; -; mRNA.
DR   EMBL; D50516; BAA09094.1; -; mRNA.
DR   EMBL; U20165; AAC50105.1; -; mRNA.
DR   EMBL; AC009960; AAX76517.1; -; Genomic_DNA.
DR   EMBL; AC073410; AAX88941.1; -; Genomic_DNA.
DR   EMBL; AC064836; AAY24146.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW70309.1; -; Genomic_DNA.
DR   EMBL; BC052985; AAH52985.1; -; mRNA.
DR   CCDS; CCDS33361.1; -. [Q13873-1]
DR   PIR; I38935; I38935.
DR   RefSeq; NP_001195.2; NM_001204.6. [Q13873-1]
DR   PDB; 2HLQ; X-ray; 1.45 A; A=33-131.
DR   PDB; 3G2F; X-ray; 2.35 A; A/B=189-517.
DR   PDB; 6UNP; X-ray; 2.30 A; A/B=188-529.
DR   PDBsum; 2HLQ; -.
DR   PDBsum; 3G2F; -.
DR   PDBsum; 6UNP; -.
DR   AlphaFoldDB; Q13873; -.
DR   SMR; Q13873; -.
DR   BioGRID; 107127; 100.
DR   DIP; DIP-5794N; -.
DR   ELM; Q13873; -.
DR   IntAct; Q13873; 51.
DR   MINT; Q13873; -.
DR   STRING; 9606.ENSP00000363708; -.
DR   BindingDB; Q13873; -.
DR   ChEMBL; CHEMBL5467; -.
DR   DrugBank; DB11639; Dibotermin alfa.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q13873; -.
DR   GuidetoPHARMACOLOGY; 1794; -.
DR   GlyConnect; 1046; 2 N-Linked glycans (2 sites).
DR   GlyGen; Q13873; 6 sites, 1 Asn glycan (1 site), 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site), 1 Thr glycan (1 site).
DR   iPTMnet; Q13873; -.
DR   PhosphoSitePlus; Q13873; -.
DR   BioMuta; BMPR2; -.
DR   DMDM; 12643724; -.
DR   CPTAC; CPTAC-2209; -.
DR   EPD; Q13873; -.
DR   jPOST; Q13873; -.
DR   MassIVE; Q13873; -.
DR   MaxQB; Q13873; -.
DR   PaxDb; Q13873; -.
DR   PeptideAtlas; Q13873; -.
DR   PRIDE; Q13873; -.
DR   ProteomicsDB; 59705; -. [Q13873-1]
DR   Antibodypedia; 19946; 541 antibodies from 36 providers.
DR   DNASU; 659; -.
DR   Ensembl; ENST00000374574.2; ENSP00000363702.2; ENSG00000204217.16. [Q13873-2]
DR   Ensembl; ENST00000374580.10; ENSP00000363708.4; ENSG00000204217.16. [Q13873-1]
DR   GeneID; 659; -.
DR   KEGG; hsa:659; -.
DR   MANE-Select; ENST00000374580.10; ENSP00000363708.4; NM_001204.7; NP_001195.2.
DR   UCSC; uc002uzf.5; human. [Q13873-1]
DR   CTD; 659; -.
DR   DisGeNET; 659; -.
DR   GeneCards; BMPR2; -.
DR   GeneReviews; BMPR2; -.
DR   HGNC; HGNC:1078; BMPR2.
DR   HPA; ENSG00000204217; Low tissue specificity.
DR   MalaCards; BMPR2; -.
DR   MIM; 178600; phenotype.
DR   MIM; 265450; phenotype.
DR   MIM; 600799; gene.
DR   neXtProt; NX_Q13873; -.
DR   OpenTargets; ENSG00000204217; -.
DR   Orphanet; 275786; Drug- or toxin-induced pulmonary arterial hypertension.
DR   Orphanet; 275777; Heritable pulmonary arterial hypertension.
DR   Orphanet; 31837; Pulmonary venoocclusive disease.
DR   PharmGKB; PA25388; -.
DR   VEuPathDB; HostDB:ENSG00000204217; -.
DR   eggNOG; KOG3653; Eukaryota.
DR   GeneTree; ENSGT00940000156449; -.
DR   HOGENOM; CLU_013015_0_0_1; -.
DR   InParanoid; Q13873; -.
DR   OMA; RDTHVNG; -.
DR   OrthoDB; 390511at2759; -.
DR   PhylomeDB; Q13873; -.
DR   TreeFam; TF314724; -.
DR   PathwayCommons; Q13873; -.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   SignaLink; Q13873; -.
DR   SIGNOR; Q13873; -.
DR   BioGRID-ORCS; 659; 24 hits in 1119 CRISPR screens.
DR   ChiTaRS; BMPR2; human.
DR   EvolutionaryTrace; Q13873; -.
DR   GeneWiki; BMPR2; -.
DR   GenomeRNAi; 659; -.
DR   Pharos; Q13873; Tchem.
DR   PRO; PR:Q13873; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q13873; protein.
DR   Bgee; ENSG00000204217; Expressed in visceral pleura and 195 other tissues.
DR   ExpressionAtlas; Q13873; baseline and differential.
DR   Genevisible; Q13873; HS.
DR   GO; GO:0005912; C:adherens junction; IDA:BHF-UCL.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0044297; C:cell body; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005905; C:clathrin-coated pit; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0044214; C:spanning component of plasma membrane; TAS:AgBase.
DR   GO; GO:0016362; F:activin receptor activity, type II; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0036122; F:BMP binding; IPI:UniProtKB.
DR   GO; GO:0098821; F:BMP receptor activity; ISS:UniProtKB.
DR   GO; GO:0045296; F:cadherin binding; IPI:ARUK-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019211; F:phosphatase activator activity; IEA:Ensembl.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IEA:Ensembl.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:1990782; F:protein tyrosine kinase binding; IPI:ARUK-UCL.
DR   GO; GO:0030546; F:signaling receptor activator activity; IEA:Ensembl.
DR   GO; GO:0005024; F:transforming growth factor beta receptor activity; IBA:GO_Central.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; ISS:BHF-UCL.
DR   GO; GO:0003176; P:aortic valve development; ISS:BHF-UCL.
DR   GO; GO:0060840; P:artery development; ISS:BHF-UCL.
DR   GO; GO:0060413; P:atrial septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001568; P:blood vessel development; IBA:GO_Central.
DR   GO; GO:0001974; P:blood vessel remodeling; ISS:BHF-UCL.
DR   GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central.
DR   GO; GO:0009267; P:cellular response to starvation; IEP:BHF-UCL.
DR   GO; GO:0002063; P:chondrocyte development; IMP:AgBase.
DR   GO; GO:0003197; P:endocardial cushion development; ISS:BHF-UCL.
DR   GO; GO:0060350; P:endochondral bone morphogenesis; ISS:AgBase.
DR   GO; GO:0072577; P:endothelial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0001935; P:endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0060173; P:limb development; IEA:Ensembl.
DR   GO; GO:0048286; P:lung alveolus development; ISS:BHF-UCL.
DR   GO; GO:0001946; P:lymphangiogenesis; ISS:BHF-UCL.
DR   GO; GO:0060836; P:lymphatic endothelial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0001893; P:maternal placenta development; IEA:Ensembl.
DR   GO; GO:0001707; P:mesoderm formation; ISS:BHF-UCL.
DR   GO; GO:0003183; P:mitral valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0003252; P:negative regulation of cell proliferation involved in heart valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:1902731; P:negative regulation of chondrocyte proliferation; IMP:AgBase.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0051148; P:negative regulation of muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0003085; P:negative regulation of systemic arterial blood pressure; IMP:BHF-UCL.
DR   GO; GO:0045906; P:negative regulation of vasoconstriction; ISS:BHF-UCL.
DR   GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0061626; P:pharyngeal arch artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048842; P:positive regulation of axon extension involved in axon guidance; IEA:Ensembl.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL.
DR   GO; GO:0061036; P:positive regulation of cartilage development; ISS:AgBase.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IDA:UniProtKB.
DR   GO; GO:0045778; P:positive regulation of ossification; ISS:BHF-UCL.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; IGI:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0030166; P:proteoglycan biosynthetic process; ISS:AgBase.
DR   GO; GO:0003177; P:pulmonary valve development; ISS:BHF-UCL.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IMP:HGNC-UCL.
DR   GO; GO:0014916; P:regulation of lung blood pressure; IMP:BHF-UCL.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:BHF-UCL.
DR   GO; GO:1905314; P:semi-lunar valve development; ISS:BHF-UCL.
DR   GO; GO:0007178; P:transmembrane receptor protein serine/threonine kinase signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0003186; P:tricuspid valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060841; P:venous blood vessel development; ISS:BHF-UCL.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL.
DR   Gene3D; 2.10.60.10; -; 1.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR015770; BMPR2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR045860; Snake_toxin-like_sf.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   PANTHER; PTHR23255:SF97; PTHR23255:SF97; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57302; SSF57302; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Disease variant; Disulfide bond; Glycoprotein; Kinase; Magnesium;
KW   Manganese; Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Receptor; Reference proteome; Serine/threonine-protein kinase; Signal;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..26
FT                   /evidence="ECO:0000255"
FT   CHAIN           27..1038
FT                   /note="Bone morphogenetic protein receptor type-2"
FT                   /id="PRO_0000024415"
FT   TOPO_DOM        27..150
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        151..171
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        172..1038
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          203..504
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          593..626
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          746..770
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          872..972
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        746..768
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        872..897
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        898..918
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        937..964
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        333
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         209..217
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305|Ref.15"
FT   BINDING         230
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305|Ref.15"
FT   BINDING         280..282
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305|Ref.15"
FT   BINDING         337..338
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305|Ref.15"
FT   BINDING         351
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305|Ref.15"
FT   MOD_RES         379
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         586
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         680
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O35607"
FT   MOD_RES         681
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O35607"
FT   CARBOHYD        55
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        110
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        126
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        34..66
FT                   /evidence="ECO:0000269|PubMed:17094948,
FT                   ECO:0007744|PDB:2HLQ"
FT   DISULFID        60..84
FT                   /evidence="ECO:0000269|PubMed:17094948,
FT                   ECO:0007744|PDB:2HLQ"
FT   DISULFID        94..117
FT                   /evidence="ECO:0000269|PubMed:17094948,
FT                   ECO:0007744|PDB:2HLQ"
FT   DISULFID        99..116
FT                   /evidence="ECO:0000269|PubMed:17094948,
FT                   ECO:0007744|PDB:2HLQ"
FT   DISULFID        118..123
FT                   /evidence="ECO:0000269|PubMed:17094948,
FT                   ECO:0007744|PDB:2HLQ"
FT   VAR_SEQ         530
FT                   /note="N -> R (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7791754"
FT                   /id="VSP_054441"
FT   VAR_SEQ         531..1038
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7791754"
FT                   /id="VSP_054442"
FT   VARIANT         60
FT                   /note="C -> Y (in PPH1; dbSNP:rs1085307172)"
FT                   /evidence="ECO:0000269|PubMed:11015450"
FT                   /id="VAR_013670"
FT   VARIANT         64
FT                   /note="S -> R (in PPH1; unknown pathological significance;
FT                   unchanged subcellular localization)"
FT                   /evidence="ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079588"
FT   VARIANT         67
FT                   /note="Y -> C (in PPH1; significant decrease in nitric
FT                   oxide synthesis by endothelial cells; dbSNP:rs1085307177)"
FT                   /evidence="ECO:0000269|PubMed:25187962"
FT                   /id="VAR_073041"
FT   VARIANT         77
FT                   /note="I -> L (in PPH1; unknown pathological significance;
FT                   unchanged subcellular localization)"
FT                   /evidence="ECO:0000269|PubMed:24936649,
FT                   ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079589"
FT   VARIANT         82
FT                   /note="Q -> H (in PPH1; dbSNP:rs1085307185)"
FT                   /evidence="ECO:0000269|PubMed:12358323"
FT                   /id="VAR_033109"
FT   VARIANT         84
FT                   /note="C -> F (in PPH1; alters alternative splicing of
FT                   BMPR2; dbSNP:rs1085307197)"
FT                   /evidence="ECO:0000269|PubMed:24936649,
FT                   ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079590"
FT   VARIANT         87
FT                   /note="H -> Y (in PPH1; unknown pathological significance;
FT                   unchanged subcellular localization)"
FT                   /evidence="ECO:0000269|PubMed:24936649,
FT                   ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079591"
FT   VARIANT         92
FT                   /note="Q -> L (in PPH1; unknown pathological significance;
FT                   unchanged subcellular localization)"
FT                   /evidence="ECO:0000269|PubMed:24936649,
FT                   ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079592"
FT   VARIANT         109
FT                   /note="Q -> H (in PPH1; unknown pathological significance;
FT                   unchanged subcellular localization)"
FT                   /evidence="ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079593"
FT   VARIANT         117
FT                   /note="C -> Y (in PPH1; dbSNP:rs1085307215)"
FT                   /evidence="ECO:0000269|PubMed:11015450"
FT                   /id="VAR_013671"
FT   VARIANT         118
FT                   /note="C -> W (in PPH1; dbSNP:rs137852743)"
FT                   /evidence="ECO:0000269|PubMed:10973254"
FT                   /id="VAR_013672"
FT   VARIANT         123
FT                   /note="C -> R (in PPH1; dbSNP:rs137852750)"
FT                   /evidence="ECO:0000269|PubMed:11115378"
FT                   /id="VAR_013673"
FT   VARIANT         123
FT                   /note="C -> S (in PPH1; dbSNP:rs137852750)"
FT                   /evidence="ECO:0000269|PubMed:11115378"
FT                   /id="VAR_013674"
FT   VARIANT         138
FT                   /note="P -> A (in PPH1; unknown pathological significance;
FT                   unchanged subcellular localization)"
FT                   /evidence="ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079594"
FT   VARIANT         162
FT                   /note="A -> P (in PPH1; unknown pathological significance;
FT                   unchanged subcellular localization)"
FT                   /evidence="ECO:0000269|PubMed:24936649,
FT                   ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079595"
FT   VARIANT         182
FT                   /note="G -> D (in PPH1; dbSNP:rs137852754)"
FT                   /evidence="ECO:0000269|PubMed:12358323"
FT                   /id="VAR_033110"
FT   VARIANT         218..1038
FT                   /note="Missing (in PPH1; changed localization to the plasma
FT                   membrane)"
FT                   /evidence="ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079596"
FT   VARIANT         224
FT                   /note="E -> D (in dbSNP:rs754343081)"
FT                   /evidence="ECO:0000269|PubMed:11115378"
FT                   /id="VAR_013675"
FT   VARIANT         248
FT                   /note="R -> G (in PPH1; unknown pathological significance;
FT                   unchanged subcellular localization)"
FT                   /evidence="ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079597"
FT   VARIANT         264
FT                   /note="D -> N (in PPH1; unknown pathological significance;
FT                   unchanged subcellular localization)"
FT                   /evidence="ECO:0000269|PubMed:24936649,
FT                   ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079598"
FT   VARIANT         298..1038
FT                   /note="Missing (in PPH1; loss of localization to the plasma
FT                   membrane; localized to the cytoplasm)"
FT                   /evidence="ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079599"
FT   VARIANT         341
FT                   /note="V -> M (in PPH1; unknown pathological significance;
FT                   unchanged subcellular localization; dbSNP:rs767882551)"
FT                   /evidence="ECO:0000269|PubMed:24936649,
FT                   ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079600"
FT   VARIANT         347
FT                   /note="C -> Y (in PPH1; dbSNP:rs137852744)"
FT                   /evidence="ECO:0000269|PubMed:10973254"
FT                   /id="VAR_013676"
FT   VARIANT         420
FT                   /note="C -> R (in PPH1; dbSNP:rs1085307324)"
FT                   /evidence="ECO:0000269|PubMed:11115378"
FT                   /id="VAR_013677"
FT   VARIANT         467
FT                   /note="K -> R (in PPH1; unknown pathological significance;
FT                   unchanged subcellular localization)"
FT                   /evidence="ECO:0000269|PubMed:28507310"
FT                   /id="VAR_079601"
FT   VARIANT         483
FT                   /note="C -> R (in PPH1; sporadic; dbSNP:rs1085307354)"
FT                   /evidence="ECO:0000269|PubMed:11015450,
FT                   ECO:0000269|PubMed:12358323"
FT                   /id="VAR_013678"
FT   VARIANT         485
FT                   /note="D -> G (in PPH1; complete loss of function;
FT                   dbSNP:rs137852745)"
FT                   /evidence="ECO:0000269|PubMed:10973254,
FT                   ECO:0000269|PubMed:11115378"
FT                   /id="VAR_013679"
FT   VARIANT         491
FT                   /note="R -> Q (in PPH1; sporadic; dbSNP:rs137852749)"
FT                   /evidence="ECO:0000269|PubMed:10903931"
FT                   /id="VAR_013680"
FT   VARIANT         491
FT                   /note="R -> W (in PPH1; dbSNP:rs137852746)"
FT                   /evidence="ECO:0000269|PubMed:10903931"
FT                   /id="VAR_013681"
FT   VARIANT         512
FT                   /note="K -> T (in PPH1; dbSNP:rs1085307364)"
FT                   /evidence="ECO:0000269|PubMed:11115378"
FT                   /id="VAR_013682"
FT   VARIANT         519
FT                   /note="N -> K (in PPH1; dbSNP:rs1085307365)"
FT                   /id="VAR_013683"
FT   VARIANT         775
FT                   /note="S -> N (unchanged subcellular localization;
FT                   dbSNP:rs2228545)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:24936649, ECO:0000269|PubMed:28507310"
FT                   /id="VAR_019996"
FT   VARIANT         863
FT                   /note="S -> N (in PPH1; abnormal subcellular localization;
FT                   significant increase in apoptosis of endothelial cells;
FT                   significant decrease in proliferation of endothelial cells;
FT                   significant decrease in nitric oxide synthesis by
FT                   endothelial cells; significant increase in endothelin 1
FT                   synthesis by endothelial cells; dbSNP:rs1006246556)"
FT                   /evidence="ECO:0000269|PubMed:25187962"
FT                   /id="VAR_073042"
FT   VARIANT         899
FT                   /note="R -> P (in PPH1; leads to constitutive activation of
FT                   the MAPK14 pathway; dbSNP:rs137852752)"
FT                   /evidence="ECO:0000269|PubMed:15965979"
FT                   /id="VAR_033111"
FT   CONFLICT        828
FT                   /note="G -> R (in Ref. 2; CAA88759)"
FT                   /evidence="ECO:0000305"
FT   STRAND          33..35
FT                   /evidence="ECO:0007829|PDB:2HLQ"
FT   TURN            42..47
FT                   /evidence="ECO:0007829|PDB:2HLQ"
FT   HELIX           48..50
FT                   /evidence="ECO:0007829|PDB:2HLQ"
FT   TURN            53..56
FT                   /evidence="ECO:0007829|PDB:2HLQ"
FT   STRAND          57..59
FT                   /evidence="ECO:0007829|PDB:2HLQ"
FT   STRAND          66..73
FT                   /evidence="ECO:0007829|PDB:2HLQ"
FT   STRAND          76..84
FT                   /evidence="ECO:0007829|PDB:2HLQ"
FT   STRAND          90..92
FT                   /evidence="ECO:0007829|PDB:2HLQ"
FT   TURN            105..109
FT                   /evidence="ECO:0007829|PDB:2HLQ"
FT   STRAND          113..118
FT                   /evidence="ECO:0007829|PDB:2HLQ"
FT   HELIX           123..125
FT                   /evidence="ECO:0007829|PDB:2HLQ"
FT   HELIX           200..202
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   STRAND          203..211
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   STRAND          216..222
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   STRAND          225..233
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           234..236
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           237..247
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   STRAND          260..267
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   STRAND          273..279
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           287..293
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           298..315
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           322..324
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   STRAND          338..341
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   STRAND          347..349
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   STRAND          359..362
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           380..382
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           385..388
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           394..396
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           397..417
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           421..423
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           437..440
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           446..453
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           471..481
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           488..490
FT                   /evidence="ECO:0007829|PDB:6UNP"
FT   HELIX           494..506
FT                   /evidence="ECO:0007829|PDB:6UNP"
SQ   SEQUENCE   1038 AA;  115201 MW;  1389923CE574B913 CRC64;
     MTSSLQRPWR VPWLPWTILL VSTAAASQNQ ERLCAFKDPY QQDLGIGESR ISHENGTILC
     SKGSTCYGLW EKSKGDINLV KQGCWSHIGD PQECHYEECV VTTTPPSIQN GTYRFCCCST
     DLCNVNFTEN FPPPDTTPLS PPHSFNRDET IIIALASVSV LAVLIVALCF GYRMLTGDRK
     QGLHSMNMME AAASEPSLDL DNLKLLELIG RGRYGAVYKG SLDERPVAVK VFSFANRQNF
     INEKNIYRVP LMEHDNIARF IVGDERVTAD GRMEYLLVME YYPNGSLCKY LSLHTSDWVS
     SCRLAHSVTR GLAYLHTELP RGDHYKPAIS HRDLNSRNVL VKNDGTCVIS DFGLSMRLTG
     NRLVRPGEED NAAISEVGTI RYMAPEVLEG AVNLRDCESA LKQVDMYALG LIYWEIFMRC
     TDLFPGESVP EYQMAFQTEV GNHPTFEDMQ VLVSREKQRP KFPEAWKENS LAVRSLKETI
     EDCWDQDAEA RLTAQCAEER MAELMMIWER NKSVSPTVNP MSTAMQNERN LSHNRRVPKI
     GPYPDYSSSS YIEDSIHHTD SIVKNISSEH SMSSTPLTIG EKNRNSINYE RQQAQARIPS
     PETSVTSLST NTTTTNTTGL TPSTGMTTIS EMPYPDETNL HTTNVAQSIG PTPVCLQLTE
     EDLETNKLDP KEVDKNLKES SDENLMEHSL KQFSGPDPLS STSSSLLYPL IKLAVEATGQ
     QDFTQTANGQ ACLIPDVLPT QIYPLPKQQN LPKRPTSLPL NTKNSTKEPR LKFGSKHKSN
     LKQVETGVAK MNTINAAEPH VVTVTMNGVA GRNHSVNSHA ATTQYANGTV LSGQTTNIVT
     HRAQEMLQNQ FIGEDTRLNI NSSPDEHEPL LRREQQAGHD EGVLDRLVDR RERPLEGGRT
     NSNNNNSNPC SEQDVLAQGV PSTAADPGPS KPRRAQRPNS LDLSATNVLD GSSIQIGEST
     QDGKSGSGEK IKKRVKTPYS LKRWRPSTWV ISTESLDCEV NNNGSNRAVH SKSSTAVYLA
     EGGTATTMVS KDIGMNCL
//
